Please check your internet connection and try again.
# Mega CV
## Overview
Mega CV is a combination product containing Megestrol Acetate and a cardiovascular agent (specific agent not identified in the request). Megestrol acetate is a synthetic progestin. The cardiovascular agent's properties depend on the specific component.
## Primary Indications
* **Megestrol Acetate Component:** Cachexia, anorexia, or unexplained weight loss associated with acquired immunodeficiency syndrome (AIDS) or cancer.
* **Cardiovascular Agent Component:** Dependent on the specific agent. Common indications include hypertension, angina, heart failure, or arrhythmias.
## Adult Dosing
* **Megestrol Acetate:**
* For anorexia/cachexia: Typically 625 mg orally once daily. Doses can range from 125 mg to 800 mg daily.
* Maximum dose: Varies depending on indication; consult specific product labeling.
* **Cardiovascular Agent:**
* Highly variable. Dependent on the specific cardiovascular agent within Mega CV. Consult specific product labeling.
## Pediatric Dosing
* **Megestrol Acetate:** Safety and efficacy in pediatric patients are not well-established. Use is generally not recommended.
* **Cardiovascular Agent:**
* Highly variable. Dependent on the specific cardiovascular agent within Mega CV. Consult specific product labeling.
## Dose Adjustments
* **Megestrol Acetate:**
* Renal impairment: No specific dose adjustment recommended.
* Hepatic impairment: No specific dose adjustment recommended, but use with caution.
* **Cardiovascular Agent:**
* Dose adjustments are frequently required based on renal function, hepatic function, and patient response. Consult specific product labeling for the cardiovascular agent.
## Contraindications
* **Megestrol Acetate:** Known hypersensitivity to megestrol acetate. Pregnancy.
* **Cardiovascular Agent:** Contraindications are specific to the individual cardiovascular agent and may include severe bradycardia, heart block, decompensated heart failure, cardiogenic shock, or known hypersensitivity to the specific agent.
## Adverse Effects
* **Megestrol Acetate:** Weight gain, increased appetite, hot flashes, hypertension, dyspnea, nausea, diarrhea, rash. Increased risk of thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism) and adrenal insufficiency.
* **Cardiovascular Agent:** Wide-ranging and dependent on the specific agent, potentially including bradycardia, hypotension, dizziness, fatigue, electrolyte imbalances, edema, and arrhythmias.
## Key Drug Interactions
* **Megestrol Acetate:** May interact with CYP3A4 inhibitors/inducers.
* **Cardiovascular Agent:** Numerous potential interactions depending on the specific agent, including other cardiovascular drugs, anti-infectives, and certain supplements.
## Monitoring
* **Megestrol Acetate:** Monitor weight, appetite, and signs of thromboembolic events. Assess for signs of adrenal insufficiency if therapy is discontinued abruptly, especially after prolonged use.
* **Cardiovascular Agent:**
* Regular blood pressure monitoring.
* Heart rate and rhythm monitoring (ECG may be indicated).
* Electrolyte levels (e.g., potassium, sodium).
* Renal and hepatic function tests.
* Signs of fluid retention (edema, weight gain).
## Clinical Pearls
* The specific cardiovascular agent in Mega CV must be clearly identified to provide comprehensive guidance.
* Weight gain with megestrol acetate may be due to fluid retention as well as increased appetite.
* Discontinuation of megestrol acetate should be considered in patients experiencing significant thromboembolic events.
* Adrenal insufficiency can occur, particularly with prolonged use and abrupt withdrawal. Consider corticosteroid coverage during stress or illness and gradual tapering if discontinuing.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature for complete and up-to-date guidance.*
